Verily’s Study Watch Rejected By FDA As Parkinson’s Drug-Development Tool
US regulators say Verily’s Study Watch – meant to be used in Parkinson’s trials – doesn’t collect data needed to assess whether a patient is truly benefitting from a drug.
You may also be interested in...
The US regulator’s report is meant to help develop new federal cybersecurity purchasing guidelines that could eventually be used to implement a cybersecurity consumer labeling program.
This week’s podcast highlights Medtech Insight’s coverage of Medtronic's decision to pull its HeartWare Ventricular Assist Device from the market and the implications of the move, as well as Biden's proposed budget that would increase funding for the US FDA.
The company had issued two recalls in the past few months for the device due to recorded deaths and adverse events, but after further analyses has decided to pull it off the market altogether.